Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Synthesis and anti-human immunodeficiency virus activity of substituted ( o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitors.

Čechová L, Dejmek M, Baszczyňski O, Šaman D, Gao L, Hu E, Stepan G, Jansa P, Janeba Z, Šimon P.

Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619826265. doi: 10.1177/2040206619826265.

2.

Xanthine-based acyclic nucleoside phosphonates with potent antiviral activity against varicella-zoster virus and human cytomegalovirus.

Baszczyňski O, Kaiser MM, Česnek M, Břehová P, Jansa P, Procházková E, Dračínský M, Snoeck R, Andrei G, Janeba Z.

Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618813050. doi: 10.1177/2040206618813050.

3.

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.

Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM.

Lancet Respir Med. 2019 Mar;7(3):239-248. doi: 10.1016/S2213-2600(18)30367-9. Epub 2018 Nov 23.

PMID:
30477763
4.

Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.

Mackman RL, Steadman VA, Dean DK, Jansa P, Poullennec KG, Appleby T, Austin C, Blakemore CA, Cai R, Cannizzaro C, Chin G, Chiva JC, Dunbar NA, Fliri H, Highton AJ, Hui H, Ji M, Jin H, Karki K, Keats AJ, Lazarides L, Lee YJ, Liclican A, Mish M, Murray B, Pettit SB, Pyun P, Sangi M, Santos R, Sanvoisin J, Schmitz U, Schrier A, Siegel D, Sperandio D, Stepan G, Tian Y, Watt GM, Yang H, Schultz BE.

J Med Chem. 2018 Nov 8;61(21):9473-9499. doi: 10.1021/acs.jmedchem.8b00802. Epub 2018 Aug 22.

PMID:
30074795
5.

Influence of the C-5 substitution in polysubstituted pyrimidines on inhibition of prostaglandin E2 production.

Kolman V, Kalčic F, Jansa P, Zídek Z, Janeba Z.

Eur J Med Chem. 2018 Aug 5;156:295-301. doi: 10.1016/j.ejmech.2018.07.010. Epub 2018 Jul 6.

PMID:
30006172
6.

Nucleobase Modified Adefovir (PMEA) Analogues as Potent and Selective Inhibitors of Adenylate Cyclases from Bordetella pertussis and Bacillus anthracis.

Česnek M, Skácel J, Jansa P, Dračínský M, Šmídková M, Mertlíková-Kaiserová H, Soto-Velasquez MP, Watts VJ, Janeba Z.

ChemMedChem. 2018 Sep 6;13(17):1779-1796. doi: 10.1002/cmdc.201800332. Epub 2018 Jul 31.

PMID:
29968968
7.

Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis.

Hsieh WC, Jansa P, Huang WC, Nižnanský M, Omara M, Lindner J.

J Thorac Cardiovasc Surg. 2018 Sep;156(3):1275-1287. doi: 10.1016/j.jtcvs.2018.04.110. Epub 2018 May 17.

PMID:
29903403
8.

Enantioselective Synthesis of All-Carbon Quaternary Centers Structurally Related to Amaryllidaceae Alkaloids.

Mikušek J, Jansa P, Jagtap PR, Vašíček T, Císařová I, Matoušová E.

Chemistry. 2018 May 18. doi: 10.1002/chem.201802493. [Epub ahead of print]

PMID:
29775495
9.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.

10.

Modulation of Prdm9-controlled meiotic chromosome asynapsis overrides hybrid sterility in mice.

Gregorova S, Gergelits V, Chvatalova I, Bhattacharyya T, Valiskova B, Fotopulosova V, Jansa P, Wiatrowska D, Forejt J.

Elife. 2018 Mar 14;7. pii: e34282. doi: 10.7554/eLife.34282.

11.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

12.

Reperfusion after pulmonary embolism - long-term follow-up, risk factors, clinical impact.

Mrozek J, Petrova J, Vaclavkova J, Janovsky V, Kraus L, Jansa P.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Jun;162(2):121-126. doi: 10.5507/bp.2018.001. Epub 2018 Jan 24.

13.

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.

McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM.

BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7.

14.

Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.

Jansa P, Pulido T.

Am J Cardiovasc Drugs. 2018 Feb;18(1):1-11. doi: 10.1007/s40256-017-0260-1. Review.

15.

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.

Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep.

16.

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.

Vizza CD, Jansa P, Teal S, Dombi T, Zhou D.

BMC Cardiovasc Disord. 2017 Sep 6;17(1):239. doi: 10.1186/s12872-017-0674-3.

17.

Polysubstituted 4,6-bis(hetero)arylpyrimidines as dual inhibitors of nitric oxide and prostaglandin E2 production.

Kolman V, Jansa P, Kalčic F, Janeba Z, Zídek Z.

Nitric Oxide. 2017 Jul 1;67:53-57. doi: 10.1016/j.niox.2017.05.001. Epub 2017 May 5.

PMID:
28483702
18.

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A.

Eur Heart J. 2017 Apr 14;38(15):1147-1155. doi: 10.1093/eurheartj/ehx025.

19.

Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A.

Steadman VA, Pettit SB, Poullennec KG, Lazarides L, Keats AJ, Dean DK, Stanway SJ, Austin CA, Sanvoisin JA, Watt GM, Fliri HG, Liclican AC, Jin D, Wong MH, Leavitt SA, Lee YJ, Tian Y, Frey CR, Appleby TC, Schmitz U, Jansa P, Mackman RL, Schultz BE.

J Med Chem. 2017 Feb 9;60(3):1000-1017. doi: 10.1021/acs.jmedchem.6b01329. Epub 2017 Jan 31.

PMID:
28075591
20.

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.

Kim NH, D'Armini AM, Grimminger F, Grünig E, Hoeper MM, Jansa P, Mayer E, Neurohr C, Simonneau G, Torbicki A, Wang C, Fritsch A, Davie N, Ghofrani HA.

Heart. 2017 Apr;103(8):599-606. doi: 10.1136/heartjnl-2016-309621. Epub 2016 Dec 23.

21.

Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.

Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O.

Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473. Epub 2016 Sep 23. Erratum in: Chest. 2018 May;153(5):1287.

22.

Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.

Šimon P, Baszczyňski O, Šaman D, Stepan G, Hu E, Lansdon EB, Jansa P, Janeba Z.

Eur J Med Chem. 2016 Oct 21;122:185-195. doi: 10.1016/j.ejmech.2016.06.026. Epub 2016 Jun 17.

PMID:
27371922
23.

Synthesis of the derivatives of 6-amino-uracil labelled with 14 C.

Elbert T, Hezký P, Jansa P.

J Labelled Comp Radiopharm. 2016 Dec;59(14):615-618. doi: 10.1002/jlcr.3405. Epub 2016 May 19.

PMID:
27197875
24.

Dual inhibition of nitric oxide and prostaglandin E2 production by polysubstituted 2-aminopyrimidines.

Zídek Z, Kverka M, Dusilová A, Kmoníčková E, Jansa P.

Nitric Oxide. 2016 Jul 1;57:48-56. doi: 10.1016/j.niox.2016.04.008. Epub 2016 Apr 29.

PMID:
27133739
25.

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.

Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M.

Lancet Respir Med. 2016 May;4(5):361-71. doi: 10.1016/S2213-2600(16)30019-4. Epub 2016 Apr 8.

PMID:
27067479
26.

Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.

Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, Mayer E, Pulido T, Wang C, Colorado P, Fritsch A, Meier C, Nikkho S, Hoeper MM.

Lancet Respir Med. 2016 May;4(5):372-80. doi: 10.1016/S2213-2600(16)30022-4. Epub 2016 Apr 8.

PMID:
27067478
27.

Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry.

Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, Bresser P, Torbicki A, Mellemkjaer S, Lewczuk J, Simkova I, Barberà JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Jaïs X, Ambroz D, Treacy C, Morsolini M, Jenkins D, Lindner J, Dartevelle P, Mayer E, Simonneau G.

Circulation. 2016 Mar 1;133(9):859-71. doi: 10.1161/CIRCULATIONAHA.115.016522. Epub 2016 Jan 29.

PMID:
26826181
28.

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.

Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ.

Eur Respir J. 2015 Dec;46(6):1711-20. doi: 10.1183/13993003.00364-2015. Epub 2015 Oct 22.

29.

Bisamidate Prodrugs of 2-Substituted 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA, adefovir) as Selective Inhibitors of Adenylate Cyclase Toxin from Bordetella pertussis.

Česnek M, Jansa P, Šmídková M, Mertlíková-Kaiserová H, Dračínský M, Brust TF, Pávek P, Trejtnar F, Watts VJ, Janeba Z.

ChemMedChem. 2015 Aug;10(8):1351-64. doi: 10.1002/cmdc.201500183. Epub 2015 Jul 1.

PMID:
26136378
30.

[Chronic thromboembolic pulmonary hypertension].

Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, Lang I, Madani MM, Ogino H, Pengo V, Mayer E.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:119-29. Turkish.

31.

[Past and present issues of the pulmonary circulation in the General University Hospital in Prague].

Jansa P, Ambrož D, Lindner J.

Vnitr Lek. 2014 Dec;60(12):1051-4. Czech.

PMID:
25692831
32.

Activation of respiratory complex II by interferon-gamma and its inhibition by pyrimidine derivatives.

Zídek Z, Jansa P, Kmoníčková E.

Neuro Endocrinol Lett. 2014;35 Suppl 2:141-8.

PMID:
25638378
33.

Malonate-based inhibitors of mammalian serine racemase: kinetic characterization and structure-based computational study.

Vorlová B, Nachtigallová D, Jirásková-Vaníčková J, Ajani H, Jansa P, Rezáč J, Fanfrlík J, Otyepka M, Hobza P, Konvalinka J, Lepšík M.

Eur J Med Chem. 2015 Jan 7;89:189-97. doi: 10.1016/j.ejmech.2014.10.043. Epub 2014 Oct 16.

PMID:
25462239
34.

Effect of macitentan on hospitalizations: results from the SERAPHIN trial.

Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N.

JACC Heart Fail. 2015 Jan;3(1):1-8. doi: 10.1016/j.jchf.2014.07.013. Epub 2014 Nov 11.

35.

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).

Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, Kim NH, Wang C, Wilkins MR, Fritsch A, Davie N, Colorado P, Mayer E.

Eur Respir J. 2015 May;45(5):1293-302. doi: 10.1183/09031936.00087114. Epub 2014 Nov 13.

36.

Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.

Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C, Bojic A, Lam CSP, Frey R, Ochan Kilama M, Unger S, Roessig L, Lang IM.

Chest. 2014 Nov;146(5):1274-1285. doi: 10.1378/chest.14-0106.

37.

[Drug therapy of pulmonary arterial hypertension in 2014].

Aschermann M, Jansa P.

Vnitr Lek. 2014 Apr;60(4):282-8. Review. Czech.

PMID:
24985985
38.

[Development of interest of pulmonary hypertension in the Czech Republic].

Jansa P.

Vnitr Lek. 2014 Apr;60(4):271-4. Czech.

PMID:
24985983
39.

Dosage compensation of an aneuploid genome in mouse spermatogenic cells.

Jansa P, Homolka D, Blatny R, Mistrik M, Bartek J, Forejt J.

Biol Reprod. 2014 Jun;90(6):124. doi: 10.1095/biolreprod.114.118497. Epub 2014 Apr 30.

PMID:
24790161
40.

Synthesis of novel purine-based coxsackievirus inhibitors bearing polycylic substituents at the N-9 position.

Dejmek M, Sála M, Plačková P, Hřebabecký H, Mascarell Borredà L, Neyts J, Dračínský M, Procházková E, Jansa P, Leyssen P, Mertlíková-Kaiserová H, Nencka R.

Arch Pharm (Weinheim). 2014 Jul;347(7):478-85. doi: 10.1002/ardp.201300431. Epub 2014 Mar 20.

PMID:
24652670
41.

Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry.

Jansa P, Jarkovsky J, Al-Hiti H, Popelova J, Ambroz D, Zatocil T, Votavova R, Polacek P, Maresova J, Aschermann M, Brabec P, Dusek L, Linhart A.

BMC Pulm Med. 2014 Mar 15;14:45. doi: 10.1186/1471-2466-14-45.

42.

Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.

Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin LJ.

Int J Cardiol. 2014 Mar 15;172(2):332-9. doi: 10.1016/j.ijcard.2013.12.179. Epub 2014 Jan 9.

43.

Chronic thromboembolic pulmonary hypertension.

Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, Lang I, Madani MM, Ogino H, Pengo V, Mayer E.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D92-9. doi: 10.1016/j.jacc.2013.10.024. Review.

44.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators.

N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.

45.

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group.

N Engl J Med. 2013 Jul 25;369(4):319-29. doi: 10.1056/NEJMoa1209657.

46.

The effect of novel [3-fluoro-(2-phosphonoethoxy)propyl]purines on the inhibition of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.

Baszczyňski O, Hocková D, Janeba Z, Holý A, Jansa P, Dračínský M, Keough DT, Guddat LW.

Eur J Med Chem. 2013 Sep;67:81-9. doi: 10.1016/j.ejmech.2013.06.032. Epub 2013 Jun 22.

PMID:
23850568
47.

Functional variants of eNOS and iNOS genes have no relationship to the portal hypertension in patients with liver cirrhosis.

Petrtyl J, Dvorak K, Jachymova M, Vitek L, Lenicek M, Urbanek P, Linhart A, Jansa P, Bruha R.

Scand J Gastroenterol. 2013 May;48(5):592-601. doi: 10.3109/00365521.2013.773459. Epub 2013 Mar 4.

PMID:
23452051
48.

Chronic thromboembolic pulmonary hypertension: role of medical therapy.

Pepke-Zaba J, Jansa P, Kim NH, Naeije R, Simonneau G.

Eur Respir J. 2013 Apr;41(4):985-90. doi: 10.1183/09031936.00201612. Epub 2013 Feb 8. Review.

49.

9-[2-(R)-(Phosphonomethoxy)propyl]-2,6-diaminopurine (R)-PMPDAP and its prodrugs: optimized preparation, including identification of by-products formed, and antiviral evaluation in vitro.

Krečmerová M, Jansa P, Dračínský M, Sázelová P, Kašička V, Neyts J, Auwerx J, Kiss E, Goris N, Stepan G, Janeba Z.

Bioorg Med Chem. 2013 Mar 1;21(5):1199-208. doi: 10.1016/j.bmc.2012.12.044. Epub 2013 Jan 9.

PMID:
23375089
50.

Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.

Procházková E, Jansa P, Březinová A, Cechová L, Mertlíková-Kaiserová H, Holý A, Dračínský M.

Bioorg Med Chem Lett. 2012 Oct 15;22(20):6405-9. doi: 10.1016/j.bmcl.2012.08.065. Epub 2012 Aug 28.

PMID:
22989530

Supplemental Content

Support Center